Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 2, 1999, Pages 568-574

  Kato, Yukio ^a   Akhteruzzaman, Sharif ^a   Hisaka, Akihiro ^b   Sugiyama, Yuichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BQ 518; CARRIER PROTEIN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO THIANYLGLYCYLLEUCYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DRUG CARRIER; ENDOTHELIN RECEPTOR ANTAGONIST; PERHYDRO 1 AZEPINYLCARBONYLLEUCYL DEXTRO TRYPTOPHYL DEXTRO TRYPTOPHAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXCRETION; DRUG PROTEIN BINDING; DRUG UPTAKE; LIVER CLEARANCE; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT;

ANIMALS; AZEPINES; BILIARY TRACT; BIOLOGICAL TRANSPORT; BLOOD PROTEINS; ENDOTHELINS; KINETICS; LIVER; MALE; OLIGOPEPTIDES; PEPTIDES, CYCLIC; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN;

EID: 0033026478     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Akhteruzzaman S, Kato Y, Hisaka A and Sugiyama Y (1999) Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. J Pharmacol Exp Ther 288:575-581.
2. Bertrams A and Ziegler K (1991a) New substrates of multispecific bile acid transporter in liver cells: Interference of some linear renin inhibiting peptides with transport protein(s) for bile acids. Biochim Biophys Acta 1073:213-220.
3. Bertrams A and Ziegler K (1991b) Hepatocellular uptake of peptides by bile acid transporters: Relationship of carrier mediated transport of linear peptides with renin inhibiting activity of multispecific bile acid carriers. Biochim Biophys Acta 1091:337-348.
4. Cathapermal SM, Foegh ML, Rau CS and Ramwell PW (1991) Disposition and tissue distribution of angiopeptin in the rat. Drug Metab Dispos 19:735-739.
5. Eckhardt U, Horz JA, Petzinger E, Stuber W, Reers M, Dickneite G, Daniel H, Wagner M, Hagenbuch B, Stieger B and Meier PJ (1996) The peptide-based thrombin inhibitor CRC 220 is a new substrate of the basolateral rat liver organic anion-transporting polypeptide. Hepatology 24:380-384.
6. Fukami T, Nagase T, Fujita K, Hayama T, Niiyama K, Mase T, Nakajima S, Fukuroda T, Saeki T, Nishikibe M, Ihara M and Yano M (1995) Structure-activity relationship of cyclic pentapeptide endothelin A receptor antagonists. J Med Chem 38:4309-4324.
7. Fukami T, Niyama K, Amano Y, Hisaka A, Fujino N, Sawasaki Y, Ihara M and Isnikawa K (1996) Cyclic pentapeptide endothelin A receptor antagonists with attenuated in vivo clearance. Chem Pharm Bull 44:609-614.
8. Gores GJ, Kost LJ, Miller LJ and Larusso NF (1989) Processing of cholecystokinin by isolated liver cells. Am J Physiol 257:G242-G248.
9. Gores GJ, Larusso NF and Miller LJ (1986) Hepatic processing of cholecystokinin peptides. I. Structural specificity and mechanism of hepatic extraction. Am J Physiol 250:G344-G349.
10. Greenfield JC, Cook KJ and O'Leary IA (1989) Disposition, metabolism and excretion of U-71038, a novel renin inhibitor peptide in the rat. Drug Metab Dispos 17:518-525.
11. A receptor antagonist BQ-485 and its preventive effect on experimental cerebral vasospasm in dogs. Biochem Biophys Res Commun 195:969-975.
12. Keppler D, Leier I and Jedlitschky G (1997) Transport of glutathione conjugates and glucuronides by the multidrug resistance proteins MRP1 and MRP2. Biol Chem 378:787-791.
13. Labmerts SWJ, Utterlinden P, Verschoor L, Van Dogen KJ and Del Pozo E (1985) Long-term treatment of acromegaly with somatostatin analogue SMS 201-995. N Engl J Med 313:1576-1580.
14. Lemaire M, Azria M, Dannecker R, Marbach P, Schweitzer A and Maurer G (1989) Disposition of sandostatin, a new synthetic somatostatin analogue in rats. Drug Metab Dispos 17:699-703.
15. Lomri N, Fitz JG and Scharschmidt BF (1996) Hepatocellular transport: Role of ATP-binding cassette proteins. Semin Liver Dis 16:201-210.
16. Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B and Stieger B (1997) Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 26:1667-1677.
17. Miyauchi S, Sawada Y, Iga T, Hanano M and Sugiyama Y (1993) Comparison for the hepatic uptake clearances of fifteen drugs with a wide range of membrane permeabilities in isolated rat hepatocytes and perfused rat liver. Pharm Res 10:434-440.
18. Moreland S (1994) Endothelin receptor antagonists: A brief review. Can J Physiol Pharmacol 71:1469-1471.
19. Müller M and Jansen PL (1997) Molecular aspects of hepatobiliary transport. Am J Physiol 272:G1285-G1303.
20. Nakamura T, Hisaka A, Sawasaki Y, Suzuki Y, Ishikawa K, Yano M and Sugiyama Y (1996) Carrier mediated active transport of BQ-123, a peptidic endothelin antagonist into rat hepatocytes. J Pharmacol Exp Ther 278:564-572.
21. A receptor antagonists FR139317 ameliorates cerebral vasospasm in dogs. Life Sci 52:1869-1874.
22. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K and Ikemoto F (1993) Antihypertensive effect of a newly synthesized endothelin antagonist BQ-123 in a genetic hypertensive model. Life Sci 52:717-724.
23. Ondetti A and Cushman DW (1981) Inhibition of the renin-angiotensin system: A new approach to the therapy of hypertension. J Med Chem 24:355-361.
24. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influeace of hepatic blood now plasma and blood cell binding and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharm Biopharm 5:625-653.
25. Shin H, Kato Y, Shitara Y, Yamada T, Nakamura T, Hisaka A and Sugiyama Y (1996) The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123. J Pharmacol Exp Ther 278:607-613.
26. Shin H, Kato Y, Yamada T, Niinuma K, Hisaka A and Sugiyama Y (1997) Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. Am J Physiol 272:G979-G986.
27. Takahashi H, Kim RB, Perry PR and Wilkinson GR (1997) Characterization of the hepatic canalicular membrane transport of a model oligopeptide: Ditekiren. J Pharmacol Exp Ther 281:297-303.
28. Yamada T, Niinuma K, Lemaire M, Terasaki T and Sugiyama Y (1996) Mechanism of the tissue distribution and biliary excretion of the cyclic peptide octreotide. J Pharmacol Exp Ther 279:1357-1364.
29. Yamada T, Niinuma K, Lemaire M, Terasaki T and Sugiyama Y (1997) Carrier-mediated hepatic uptake of the cationic cyclopeptide octreotide in rats. Drug Metab Dispos 25:536-543.
30. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
31. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 264:G36-G44.
32. Yamazaki M, Suzuki H and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497-513.
33. Ziegler K, Frimmer M, Kessler H and Haupt A (1988) Azidobenzodiamido-008, a new photosensitive substrate for the 'multispecific bile acid transporter' of hepatocytes: Evidence for a common transport system for bile acids and cyclosomatostatins in basolateral membranes. Biochim Biophys Acta 945:263-272.
34. Ziegler K, Kolac C and Ising W (1994) ATP-dependent transport of the linear renin-inhibiting peptide EMD-51921 by canalicular plasma membrane vesicles of rat liver: Evidence of drug-stimulatable ATP-hydrolysis. Biochim Biophys Acta 1196:209-217.
35. Ziegler K, Lins W and Frimmer M (1991) Hepatocellular uptake of cyclosomatostatins: Evidence for a carrier system related to the multispecific bile acid transporter. Biochim Biophys Acta 1061:287-296.